| Benfluorex and valvular heart disease: a cohort study of a million people with diabetes mellitus. | |
| | |
MedLine Citation:
|
PMID: 20945504 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
PURPOSE: To evaluate and quantify in diabetic patients treated with benfluorex in France, a fenfluramine-derivated product, a possible increase in risk of valvular heart disease, previously suggested by several published case reports. METHODS: This was a French comparative cohort study using data from two large national linked databases, health insurance system (SNIIRAM) and hospitalization (PMSI). Patients aged 40-69 years with reimbursement for oral antidiabetic and/or insulin in 2006 were eligible. Exposed patients were defined as patients with at least one benfluorex reimbursement in 2006. Selected admission diagnoses of interest in 2007 and 2008 PMSI databases were valvular insufficiency for any cause, mitral insufficiency, aortic insufficiency, and valvular replacement surgery with cardiopulmonary bypass. Relative risks (RR) were adjusted on gender, age, and history of chronic cardiovascular disease. RESULTS: A total of 1,048173 diabetic patients were included, with 43,044 (4.1%) exposed to benfluorex. The risk of hospitalization in 2007 and 2008 for any cardiac valvular insufficiency was higher in the benfluorex group: crude RR=2.9 [95% confidence interval 2.2-3.7] and adjusted RR=3.1 [2.4-4.0], with a lower risk for patients with lower cumulative dose of benfluorex. Adjusted RR for mitral insufficiency and aortic insufficiency admissions were 2.5 [1.9-3.7] and 4.4 [3.0-6.6], respectively. Adjusted RR for valvular replacement surgery was 3.9 [2.6-6.1]. CONCLUSIONS: Benfluorex in diabetic patients was significantly associated with hospitalization for valvular heart disease in the 2 years following benfluorex exposure. Linkage between SNIIRAM and PMSI databases is in France a valuable tool to quantify the risk of serious adverse drug reactions. |
| | |
Authors:
|
Alain Weill; Michel Païta; Philippe Tuppin; Jean-Paul Fagot; Anke Neumann; Dominique Simon; Philippe Ricordeau; Jean-Louis Montastruc; Hubert Allemand |
Related Documents
:
|
19538234 - Australia's national trends in the incidence of type 1 diabetes in 0-14-year-olds, 2000... 19105694 - Gender risk of nonfatal stroke in type 2 diabetic patients differs depending on the typ... 9146434 - The role of diabetes mellitus in the higher prevalence of tuberculosis among hispanics. 18565394 - Clinical efficacy of drug-eluting stents in diabetic patients: a meta-analysis. 9283794 - Role of igf binding protein-1 in the dawn phenomenon and glycemic control in children a... 3040384 - Phosphoinositides turnover and insulin secretion in pancreatic islets. |
Publication Detail:
|
Type: Journal Article Date: 2010-10-13 |
Journal Detail:
|
Title: Pharmacoepidemiology and drug safety Volume: 19 ISSN: 1099-1557 ISO Abbreviation: Pharmacoepidemiol Drug Saf Publication Date: 2010 Dec |
Date Detail:
|
Created Date: 2010-11-25 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9208369 Medline TA: Pharmacoepidemiol Drug Saf Country: England |
Other Details:
|
Languages: eng Pagination: 1256-62 Citation Subset: IM |
Copyright Information:
|
Copyright © 2010 John Wiley & Sons, Ltd. |
Affiliation:
|
Direction de la Stratégie, des Études et des Statistiques, Caisse Nationale de l'Assurance Maladie, Paris, France. alain.weill@cnamts.fr |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Unveiling the methylation status of CpG dinucleotides in the substituted segment of the human p53 kn...
Next Document: Methods for drug safety signal detection in longitudinal observational databases: LGPS and LEOPARD.